The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Gefitinib in the treatment of advanced, refractory non-small-cell lung cancer: results in 124 patients.

To evaluate the feasibility, toxicity, and efficacy of oral gefitinib (ZD1839, Iressa) in patients with refractory non-small-cell lung cancer (NSCLC) treated in a community-based setting. One hundred twenty-four patients with advanced, refractory NSCLC received treatment with gefitinib 250 mg orally each day. Ninety-six percent of patients had received >or= 1 previous chemotherapy regimens and 79% had received previous platinum and taxane therapy. Patients were evaluated for response after 6-12 weeks of daily gefitinib therapy; patients with objective response or stable disease continued gefitinib until disease progression occurred. Gefitinib was well-tolerated in these patients with advanced, refractory NSCLC. There were no grade 4 toxicities, and grade 3 skin toxicity and diarrhea were observed in only 4% and 2% of patients, respectively. Nine of 120 evaluable patients (8%) had partial responses to treatment; however, 54 patients (45%) had no evidence of progression at first reevaluation, and a total of 35 patients (29%) reported improvement in lung cancer-related symptoms while receiving gefitinib. Median survival for the entire group was 6.5 months, with a 1-year survival rate of 35%. Gefitinib is active and very well-tolerated in patients with advanced, refractory NSCLC. Although the major response rate was low, nearly 50% of patients derived substantial palliative benefit from gefitinib therapy. The median survival of 6.5 months achieved in this large group of relatively unselected patients is unprecedented in the third-line treatment setting, and compares favorably to other available second-line treatment including docetaxel. A therapeutic trial of gefitinib should be considered in all patients with refractory NSCLC.[1]


  1. Gefitinib in the treatment of advanced, refractory non-small-cell lung cancer: results in 124 patients. Hainsworth, J.D., Mainwaring, M.G., Thomas, M., Porter, L.L., Gian, V.G., Jones, S.F., Greco, F.A. Clinical lung cancer. (2003) [Pubmed]
WikiGenes - Universities